Piperacillin Sodium

• CAT Number: A000950
• CAS Number: 59703-84-3
• Molecular Formula: C23H26N5NaO7S
• Molecular Weight: 539.50
• Purity: ≥95%
• Synonyms: Sodium piperacillin; PIPERACILLIN SODIUM SALT; 59703-84-3; Piperacillin (sodium); UNII-M98T69Q7HP
• Target: Bacterial
• Storage: -20°C
• IUPAC Name: sodium;(2S,5R,6R)-6-[[(2R)-2-[(4-ethyl-2,3-dioxopiperazine-1-carbonyl)amino]-2-phenylacetyl]amino]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylate
• InChI: InChI=1S/C23H27N5O7S.Na/c1-4-26-10-11-27(19(32)18(26)31)22(35)25-13(12-8-6-5-7-9-12)16(29)24-14-17(30)28-15(21(33)34)23(2,3)36-20(14)28;/h5-9,13-15,20H,4,10-11H2,1-3H3,(H,24,29)(H,25,35)(H,33,34);/q;+1/p-1/t13-,14-,15+,20-;/m1./s1
• InChIKey: WCMIIGXFCMNQDS-IDYPWDAWSA-M
• SMILES: CCN1CCN(C(=O)C1=O)C(=O)N[C@H](C2=CC=CC=C2)C(=O)N[C@H]3[C@@H]4N(C3=O)[C@H](C(S4)(C)C)C(=O)[O-].[Na+]

Piperacillin Sodium（Cat No.:A000950）is a broad-spectrum, beta-lactam antibiotic belonging to the penicillin class, widely used to treat severe bacterial infections. Effective against various gram-negative and gram-positive bacteria, it works by inhibiting cell wall synthesis, leading to bacterial cell death. Piperacillin Sodium is commonly administered in combination with tazobactam, a beta-lactamase inhibitor, to enhance its efficacy against beta-lactamase-producing bacteria. It is used in hospital settings to manage infections such as pneumonia, urinary tract infections, and sepsis. Its potency and broad-spectrum action make it a key option for critical infections.

Reference

1: Leung E, Venkatesan N, Ly SC, Scheetz MH. Physical compatibility of vancomycin
and piperacillin sodium-tazobactam at concentrations typically used during
prolonged infusions. Am J Health Syst Pharm. 2013 Jul 1;70(13):1163-6. doi:
10.2146/ajhp120409. PubMed PMID: 23784164.

2: Gupta VD, Ling J. Stability of piperacillin sodium after reconstitution in
0.9% sodium chloride injection and storage in polypropylene syringes for
pediatric use. Int J Pharm Compd. 2001 May-Jun;5(3):230-1. PubMed PMID: 23981892.

3: Zhang Y, Xu QA, Trissel LA, Williams KY. Compatibility and stability of
linezolid injection admixed with aztreonam or piperacillin sodium. J Am Pharm
Assoc (Wash). 2000 Jul-Aug;40(4):520-4. PubMed PMID: 10932462.

4: Hahn Y, Son E. Electrochemical behavior and differential pulse polarographic
determination of piperacillin sodium. Arch Pharm Res. 2000 Jun;23(3):197-201.
PubMed PMID: 10896047.

5: Park TW, Le-Bui LP, Chung KC, Rho JP, Gill MA. Stability of piperacillin
sodium-tazobactam sodium in peritoneal dialysis solutions. Am J Health Syst
Pharm. 1995 Sep 15;52(18):2022-4. PubMed PMID: 8528873.

6: Chung KC, Moon YS, Chin A, Ulrich RW, Gill MA. Compatibility of ondansetron
hydrochloride and piperacillin sodium-tazobactam sodium during simulated Y-site
administration. Am J Health Syst Pharm. 1995 Jul 15;52(14):1554-6. PubMed PMID:
7552901.

7: Moon YS, Chung KC, Chin A, Gill MA. Stability of piperacillin
sodium-tazobactam sodium in polypropylene syringes and polyvinyl chloride
minibags. Am J Health Syst Pharm. 1995 May 1;52(9):999-1001. PubMed PMID:
7641040.

8: Moscato G, Galdi E, Scibilia J, Dellabianca A, Omodeo P, Vittadini G, Biscaldi
GP. Occupational asthma, rhinitis and urticaria due to piperacillin sodium in a
pharmaceutical worker. Eur Respir J. 1995 Mar;8(3):467-9. PubMed PMID: 7789496.

9: Mathew M, Das Gupta V, Bethea C. Stability of piperacillin sodium in the
presence of tazobactam sodium in 5% dextrose and normal saline injections. J Clin
Pharm Ther. 1994 Dec;19(6):397-9. PubMed PMID: 7876373.

10: Choi JS, Burm JP, Jhee SS, Chin A, Ulrich RW, Gill MA. Stability of
piperacillin sodium-tazobactam sodium and ranitidine hydrochloride in 0.9% sodium
chloride injection during simulated Y-site administration. Am J Hosp Pharm. 1994
Sep 15;51(18):2273-6. PubMed PMID: 7801988.